Leishmaniasis Clinical Trials

3 recruiting

Leishmaniasis Trials at a Glance

14 actively recruiting trials for leishmaniasis are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Baghdad, Bologna, and Brasília. Lead sponsors running leishmaniasis studies include Hayder Adnan Fawzi, Fundacion Nacional de Dermatologia, and Al-Mustafa University College.

Browse leishmaniasis trials by phase

Treatments under study

About Leishmaniasis Clinical Trials

Looking for clinical trials for Leishmaniasis? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Leishmaniasis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Leishmaniasis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting

Diagnosis and Treatment of Leishmania Infections

LeishmaniasisSkin Diseases, ParasiticEuglenozoa Infections+1 more
National Institute of Allergy and Infectious Diseases (NIAID)289 enrolled1 locationNCT00344188
Recruiting
Phase 3

Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.

Leishmaniasis, Cutaneous
Universidad de Antioquia96 enrolled1 locationNCT06822478
Recruiting

LEISH-PED: Study on Leishmaniasis in Children

Leishmania Infantum DiseaseLeishmaniasis, VisceralLeishmaniasis, Cutaneous+1 more
Meyer Children's Hospital IRCCS200 enrolled1 locationNCT07504757
Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

Streptococcus PneumoniaeMalariaMeningitis+55 more
Institut Pasteur du Cambodge10,000 enrolled1 locationNCT07358910
Recruiting
Phase 2

Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate

Cutaneous Leishmaniasis
Al-Mustafa University College80 enrolled1 locationNCT06798402
Recruiting
Phase 2

Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis

Cutaneous Leishmaniasis
Hayder Adnan Fawzi40 enrolled1 locationNCT06797544
Recruiting
Phase 3

Randomised Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan

Old World Cutaneous Leishmaniasis
Medecins Sans Frontieres, Netherlands832 enrolled2 locationsNCT04268524
Recruiting
Phase 2

Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis With Inhaled Pentamidine Plus Oral Miltefosine

Mucosal Leishmaniasis
Fundacion Nacional de Dermatologia30 enrolled1 locationNCT06550609
Recruiting
Phase 2

Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis

Cutaneous Leishmaniasis
Hayder Adnan Fawzi40 enrolled1 locationNCT06798415
Recruiting

Visceral Leishmaniasis in Emilia-Romagna (Leishmania-2019)

Leishmaniasis, Visceral
IRCCS Azienda Ospedaliero-Universitaria di Bologna300 enrolled5 locationsNCT06793111
Recruiting
Not Applicable

Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers

Leishmaniasis
IRCCS Sacro Cuore Don Calabria di Negrar170 enrolled1 locationNCT06307171
Recruiting

Clinical Prognostic Score to Predict Relapse in VL

Visceral Leishmaniasis
Institute of Tropical Medicine, Belgium741 enrolled1 locationNCT05602610
Recruiting
Phase 2Phase 3

Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly

Leishmaniasis, MucocutaneousLeishmaniasis; Brazilian
University of Brasilia100 enrolled1 locationNCT06040489
Recruiting
Phase 1

The comparison between topical terbinafine and placebo in the treatment of cutaneous leishmaniasis

cutaneou leishmaniasis
Kerman medical university88 enrolled1 locationACTRN12609000113257